All In Biotech

NDA 020560 · Organon

Fosamax

Alendronate Sodium · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Sep 29, 1995

Approved uses

13

Original approval plus efficacy supplements

Registered trials

181

59 Phase 3, 7 recruiting

FAERS reports

83,679

66,990 serious, 10,774 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 12, 2026.

FOSAMAX is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1 , 1.2 ) Treatment to increase bone mass in men with osteoporosis ( 1.3 ) Treatment of glucocorticoid-induced osteoporosis ( 1.4 ) Treatment of Paget's disease of bone ( 1.5 ) Limitations of use : Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women FOSAMAX ® is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, FOSAMAX increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies (14.1) .] 1.2 Prevention of Osteoporosis in Postmenopausal Women FOSAMAX is indicated for the prevention of postmenopausal osteoporosis [see Clinical Studies (14.2) ] . 1.3 Treatment to Increase Bone Mass in Men with Osteoporosis FOSAMAX is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.3) ] . 1.4 Treatment of Glucocorticoid-Induced Osteoporosis FOSAMAX is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see Clinical Studies (14.4) ] . 1.5 Treatment of Paget's Disease of Bone FOSAMAX is indicated for the treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease....

Mechanism: Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • FOSAMAX · ALENDRONATE SODIUM EQ 70MG BASE · TABLET, ORAL · Prescription · TE AB
  • FOSAMAX · ALENDRONATE SODIUM EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • FOSAMAX · ALENDRONATE SODIUM EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • FOSAMAX · ALENDRONATE SODIUM EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • FOSAMAX · ALENDRONATE SODIUM EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Alendronate" as an intervention, any sponsor and status, largest first.

All 181 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain13,040
  • fatigue12,258
  • drug ineffective11,759
  • femur fracture11,065
  • arthralgia10,508
  • rheumatoid arthritis10,154
  • alopecia9,989
  • abdominal discomfort9,939
  • systemic lupus erythematosus9,388
  • pemphigus9,118
  • rash8,790
  • glossodynia8,478

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,094
20053,438
20063,302
20073,751
20083,254
20093,260
20104,088
20114,620
20128,031
20133,906
20142,882
20152,893
20162,519
20172,434
20182,492
20192,771
20203,385
20214,878
20224,270
20232,985
20244,689
20254,240
20262,496

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fosamax (Alendronate Sodium)

2024 spending

$446K

Beneficiaries

459

1,437 claims

Per beneficiary

$971

$34.22 per unit

View as table
YearSpending
2020$0
2021$131,892
2022$477,192
2023$449,342
2024$445,614

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,038 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.